Test ID BLOD1339 Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum
Useful For
Trough level quantitation for evaluation of patients undergoing therapy with infliximab, with signs and symptoms of loss of response to therapy.
Specimen Type
Serum RedSpecimen Required
Patient Preparation:
1. Draw blood immediately before next scheduled dose (trough specimen).
2. For 12 hours before specimen collection do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into plastic vial within 2 hours of collection.
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | OK |
Gross icterus | Reject |
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum Red | Refrigerated (preferred) | 28 days | |
Frozen | 28 days |
Day(s) Performed
Monday through Friday
Report Available
3 to 6 daysMethod Name
INFXR, INFX: Selective Reaction Monitoring Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
INXAB: Electrochemiluminescent Bridging Immunoassay with Acid Dissociation
Performing Laboratory
Mayo Clinic Laboratories in RochesterCPT Code Information
80230
82397-(if appropriate)
Reporting Name
Infliximab QN with Reflex to Ab, SReference Values
INFLIXIMAB QUANTITATION:
Limit of quantitation is 1.0 mcg/mL. Therapeutic ranges are disease specific.
Pediatric reference ranges are not established.
INFLIXIMAB ANTIBODIES
Absence of antibodies to infliximab (ATI) is defined as <50 U/mL
Presence of ATI is reported as positive when concentrations are ≥50 U/mL
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.Forms
If not ordering electronically, complete, print, and send 1 of the following with specimen:
-Gastroenterology and Hepatology Test Request (T728)
-Therapeutics Test Request (T831)
-General Request (T239)
Special Instructions
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
INFX | Infliximab, S | No | Yes |
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
INXAB | Infliximab Ab, S | No | No |
Testing Algorithm
Infliximab will be performed by liquid chromatography-tandem mass spectrometry on all specimens. When infliximab results are below 5.1 mcg/mL, testing for antibodies to infliximab will be performed at an additional charge.
For more information see Ulcerative Colitis and Crohn Disease Therapeutic Drug Monitoring Algorithm
SANFORD LABORATORY INTERFACE BUILD INFORMATION
Result Code | Result Code Description |
---|---|
18564 | Infliximab, S |
18565 | Interpretation |